Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B

Mieli-Vergani G., Bansal S., Daniel J. F., Kansu Tanca A., Kelly D., Martin C., ...More

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, vol.73, no.2, pp.156-160, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 73 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.1097/mpg.0000000000003118
  • Journal Name: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.156-160
  • Keywords: hepatitis B e antigen loss, hepatitis B surface antigen loss, nucleoside analogue, randomized trial, treatment, INTERFERON TREATMENT, THERAPY, GUIDELINES, OLD
  • Ankara University Affiliated: Yes

Abstract

Objective: Treatment guidelines for chronic hepatitis B (CHB) do not recommend antiviral therapy for patients in the immune-tolerant phase of the disease, which generally occurs in children who acquire hepatitis B virus (HBV) vertically and may last for decades. On the basis of promising results of a pilot study, we conducted a randomized, controlled, multicenter study to evaluate the efficacy and safety of antiviral therapy in children and adolescents with immune-tolerant CHB.